

Jin Li

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/250098/publications.pdf>

Version: 2024-02-01

199
papers

7,036
citations

87843

38
h-index

69214

77
g-index

205
all docs

205
docs citations

205
times ranked

9368
citing authors

#	ARTICLE	IF	CITATIONS
1	Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Apatinib in Patients With Chemotherapy-Refractory Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction. <i>Journal of Clinical Oncology</i> , 2016, 34, 1448-1454.	0.8	756
2	Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): a randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet Oncology</i> , The, 2015, 16, 619-629.	5.1	574
3	Apatinib for Chemotherapy-Refractory Advanced Metastatic Gastric Cancer: Results From a Randomized, Placebo-Controlled, Parallel-Arm, Phase II Trial. <i>Journal of Clinical Oncology</i> , 2013, 31, 3219-3225.	0.8	454
4	The Chinese Society of Clinical Oncology (CSCO): clinical guidelines for the diagnosis and treatment of gastric cancer. <i>Cancer Communications</i> , 2019, 39, 1-31.	3.7	418
5	The Chinese Society of Clinical Oncology (CSCO): Clinical guidelines for the diagnosis and treatment of gastric cancer, 2021. <i>Cancer Communications</i> , 2021, 41, 747-795.	3.7	323
6	MicroRNAs activate gene transcription epigenetically as an enhancer trigger. <i>RNA Biology</i> , 2017, 14, 1326-1334.	1.5	262
7	Cognitive frailty, a novel target for the prevention of elderly dependency. <i>Ageing Research Reviews</i> , 2015, 20, 1-10.	5.0	231
8	Safety and pharmacokinetics of novel selective vascular endothelial growth factor receptor-2 inhibitor YN968D1 in patients with advanced malignancies. <i>BMC Cancer</i> , 2010, 10, 529.	1.1	220
9	Effect of Fruquintinib vs Placebo on Overall Survival in Patients With Previously Treated Metastatic Colorectal Cancer. <i>JAMA - Journal of the American Medical Association</i> , 2018, 319, 2486.	3.8	202
10	Efficacy and Tolerability of First-Line Cetuximab Plus Leucovorin, Fluorouracil, and Oxaliplatin (FOLFOX-4) Versus FOLFOX-4 in Patients With <i>c-RAS</i> Wild-Type Metastatic Colorectal Cancer: The Open-Label, Randomized, Phase III TAILOR Trial. <i>Journal of Clinical Oncology</i> , 2018, 36, 3031-3039.	0.8	159
11	Approved CAR T cell therapies: ice bucket challenges on glaring safety risks and long-term impacts. <i>Drug Discovery Today</i> , 2018, 23, 1175-1182.	3.2	142
12	The current status of treatment for colorectal cancer in China. <i>Medicine (United States)</i> , 2017, 96, e8242.	0.4	111
13	MicroRNA-421 regulated by HIF-1 α promotes metastasis, inhibits apoptosis, and induces cisplatin resistance by targeting E-cadherin and caspase-3 in gastric cancer. <i>Oncotarget</i> , 2016, 7, 24466-24482.	0.8	103
14	Identification of stem-like cells and clinical significance of candidate stem cell markers in gastric cancer. <i>Oncotarget</i> , 2016, 7, 9815-9831.	0.8	90
15	Polarization of Monocytic Myeloid-Derived Suppressor Cells by Hepatitis B Surface Antigen Is Mediated via ERK/IL-6/STAT3 Signaling Feedback and Restrains the Activation of T Cells in Chronic Hepatitis B Virus Infection. <i>Journal of Immunology</i> , 2015, 195, 4873-4883.	0.4	82
16	BMI1 and Mel-18 oppositely regulate carcinogenesis and progression of gastric cancer. <i>Molecular Cancer</i> , 2010, 9, 40.	7.9	77
17	Radical abdominal trachelectomy for cervical malignancies: Surgical, oncological and fertility outcomes in 62 patients. <i>Gynecologic Oncology</i> , 2011, 121, 565-570.	0.6	77
18	miRNA-99b-5p suppresses liver metastasis of colorectal cancer by down-regulating mTOR. <i>Oncotarget</i> , 2015, 6, 24448-24462.	0.8	76

#	ARTICLE	IF	CITATIONS
19	Early presence of anti-angiogenesis-related adverse events as a potential biomarker of antitumor efficacy in metastatic gastric cancer patients treated with apatinib: a cohort study. <i>Journal of Hematology and Oncology</i> , 2017, 10, 153.	6.9	70
20	Expert consensus on multidisciplinary therapy of colorectal cancer with lung metastases (2019) <i>Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 70</i>	6.9	69
21	Concordance of immune checkpoints within tumor immune contexture and their prognostic significance in gastric cancer. <i>Molecular Oncology</i> , 2016, 10, 1551-1558.	2.1	66
22	Randomized double-blind placebo-controlled phase 2 study of bemarituzumab combined with modified FOLFOX6 (mFOLFOX6) in first-line (1L) treatment of advanced gastric/gastroesophageal junction adenocarcinoma (FIGHT).. <i>Journal of Clinical Oncology</i> , 2021, 39, 160-160.	0.8	64
23	Abdominal radical trachelectomy: Is it safe for IB1 cervical cancer with tumors ≤ 2 cm?. <i>Gynecologic Oncology</i> , 2013, 131, 87-92.	0.6	61
24	Associations of HLA-DP Variants with Hepatitis B Virus Infection in Southern and Northern Han Chinese Populations: A Multicenter Case-Control Study. <i>PLoS ONE</i> , 2011, 6, e24221.	1.1	60
25	Pri-miR-124 rs531564 and pri-miR-34b/c rs4938723 Polymorphisms Are Associated with Decreased Risk of Esophageal Squamous Cell Carcinoma in Chinese Populations. <i>PLoS ONE</i> , 2014, 9, e100055.	1.1	59
26	Functional Genetic Approach Identifies MET, HER3, IGF1R, INSR Pathways as Determinants of Lapatinib Unresponsiveness in HER2-Positive Gastric Cancer. <i>Clinical Cancer Research</i> , 2014, 20, 4559-4573.	3.2	59
27	MicroRNA-940 promotes tumor cell invasion and metastasis by downregulating ZNF24 in gastric cancer. <i>Oncotarget</i> , 2015, 6, 25418-25428.	0.8	56
28	Incidence, risk factors and treatment of cervical stenosis after radical trachelectomy: A systematic review. <i>European Journal of Cancer</i> , 2015, 51, 1751-1759.	1.3	56
29	Final results and outcomes by prior bevacizumab exposure, skin toxicity, and hypomagnesaemia from ASPCCCT: randomized phase 3 non-inferiority study of panitumumab versus cetuximab in chemorefractory wild-type KRAS exon 2 metastatic colorectal cancer. <i>European Journal of Cancer</i> , 2016, 68, 51-59.	1.3	56
30	Label-free Proteomic Analysis of Exosomes Derived from Inducible Hepatitis B Virus-Replicating HepAD38 Cell Line. <i>Molecular and Cellular Proteomics</i> , 2017, 16, S144-S160.	2.5	56
31	Safety and efficacy of fruqintinib in patients with previously treated metastatic colorectal cancer: a phase Ib study and a randomized double-blind phase II study. <i>Journal of Hematology and Oncology</i> , 2017, 10, 22.	6.9	50
32	Breakthroughs in modern cancer therapy and elusive cardiotoxicity: Critical research practice gaps, challenges, and insights. <i>Medicinal Research Reviews</i> , 2018, 38, 325-376.	5.0	50
33	Implication of combined PD-L1/PD-1 blockade with cytokine-induced killer cells as a synergistic immunotherapy for gastrointestinal cancer. <i>Oncotarget</i> , 2016, 7, 10332-10344.	0.8	50
34	The safety of apatinib for the treatment of gastric cancer. <i>Expert Opinion on Drug Safety</i> , 2018, 17, 1145-1150.	1.0	49
35	Prognostic Value of FGFR Gene Amplification in Patients with Different Types of Cancer: A Systematic Review and Meta-Analysis. <i>PLoS ONE</i> , 2014, 9, e105524.	1.1	47
36	Multiple receptor tyrosine kinase activation attenuates therapeutic efficacy of the fibroblast growth factor receptor 2 inhibitor AZD4547 in <i>FGFR2</i> amplified gastric cancer. <i>Oncotarget</i> , 2015, 6, 2009-2022.	0.8	46

#	ARTICLE	IF	CITATIONS
37	A Phase I study of safety and pharmacokinetics of fruquintinib, a novel selective inhibitor of vascular endothelial growth factor receptor-1, -2, and -3 tyrosine kinases in Chinese patients with advanced solid tumors. <i>Cancer Chemotherapy and Pharmacology</i> , 2016, 78, 259-269.	1.1	45
38	Primary non-Hodgkinâ€™s lymphoma of the breast: eight-year follow-up experience. <i>International Journal of Hematology</i> , 2008, 87, 491-497.	0.7	42
39	The Combination of RAD001 and MK-2206 Exerts Synergistic Cytotoxic Effects against PTEN Mutant Gastric Cancer Cells: Involvement of MAPK-Dependent Autophagic, but Not Apoptotic Cell Death Pathway. <i>PLoS ONE</i> , 2014, 9, e85116.	1.1	39
40	Neurotensin is an anti-thermogenic peptide produced by lymphatic endothelial cells. <i>Cell Metabolism</i> , 2021, 33, 1449-1465.e6.	7.2	38
41	The Predictive and Prognostic Value of Early Metabolic Response Assessed by Positron Emission Tomography in Advanced Gastric Cancer Treated with Chemotherapy. <i>Clinical Cancer Research</i> , 2016, 22, 1603-1610.	3.2	37
42	Prevalence of psychological disorders in the COVID-19 epidemic in China: A real world cross-sectional study. <i>Journal of Affective Disorders</i> , 2021, 281, 312-320.	2.0	37
43	On what scale does it benefit the patients if uterine arteries were preserved during ART?. <i>Gynecologic Oncology</i> , 2014, 134, 154-159.	0.6	36
44	Discoidin domain receptors orchestrate cancer progression: A focus on cancer therapies. <i>Cancer Science</i> , 2021, 112, 962-969.	1.7	35
45	Anlotinib Monotherapy for Refractory Metastatic Colorectal Cancer: A Double-Blinded, Placebo-Controlled, Randomized Phase III Trial (ALTER0703). <i>Oncologist</i> , 2021, 26, e1693-e1703.	1.9	35
46	miR-449b rs10061133 and miR-4293 rs12220909 polymorphisms are associated with decreased esophageal squamous cell carcinoma in a Chinese population. <i>Tumor Biology</i> , 2015, 36, 8789-8795.	0.8	34
47	Histone-Related Genes Are Hypermethylated in Lung Cancer and Hypermethylated <i>HIST1H4F</i> Could Serve as a Pan-Cancer Biomarker. <i>Cancer Research</i> , 2019, 79, 6101-6112.	0.4	34
48	Effects of <i>IGF2BP2</i> , <i>KCNQ1</i> and <i>GCKR</i> polymorphisms on clinical outcome in metastatic gastric cancer treated with EOF regimen. <i>Pharmacogenomics</i> , 2015, 16, 959-970.	0.6	32
49	Current Molecular Targeted Therapy in Advanced Gastric Cancer: A Comprehensive Review of Therapeutic Mechanism, Clinical Trials, and Practical Application. <i>Gastroenterology Research and Practice</i> , 2016, 2016, 1-9.	0.7	31
50	Protocadherinâ€8 promotes invasion and metastasis via laminin subunit Î²2 in gastric cancer. <i>Cancer Science</i> , 2018, 109, 732-740.	1.7	30
51	Predictive factors of para-aortic lymph nodes metastasis in cervical cancer patients: a retrospective analysis based on 723 para-aortic lymphadenectomy cases. <i>Oncotarget</i> , 2017, 8, 51840-51847.	0.8	30
52	Differential microRNA expression profiling in primary tumors and matched liver metastasis of patients with colorectal cancer. <i>Oncotarget</i> , 2017, 8, 35783-35791.	0.8	29
53	Current Strategy for the Treatment of Ovarian Germ Cell Tumors: Role of Extensive Surgery. <i>Current Treatment Options in Oncology</i> , 2016, 17, 44.	1.3	28
54	Famitinib versus placebo in the treatment of refractory metastatic colorectal cancer: a multicenter, randomized, double-blinded, placebo-controlled, phase II clinical trial. <i>Chinese Journal of Cancer</i> , 2017, 36, 97.	4.9	28

#	ARTICLE	IF	CITATIONS
55	FIGHT: A randomized, double-blind, placebo-controlled, phase II study of bemarituzumab (bema) combined with modified FOLFOX6 in 1L FGFR2b+ advanced gastric/gastroesophageal junction adenocarcinoma (GC).. <i>Journal of Clinical Oncology</i> , 2021, 39, 4010-4010.	0.8	27
56	Guide Positioning Sequencing identifies aberrant DNA methylation patterns that alter cell identity and tumor-immune surveillance networks. <i>Genome Research</i> , 2019, 29, 270-280.	2.4	25
57	The Survival Rate and Surgical Morbidity of Abdominal Radical Trachelectomy Versus Abdominal Radical Hysterectomy for Stage IB1 Cervical Cancer. <i>Annals of Surgical Oncology</i> , 2016, 23, 2953-2958.	0.7	24
58	Serum Levels of ApoA1 and ApoA2 Are Associated with Cognitive Status in Older Men. <i>BioMed Research International</i> , 2015, 2015, 1-10.	0.9	23
59	Prognostic factors and role of salvage surgery in chemorefractory ovarian germ cell malignancies: A study in Chinese patients. <i>Gynecologic Oncology</i> , 2007, 105, 769-775.	0.6	22
60	Oxidative Stress-Related Genetic Polymorphisms Are Associated with the Prognosis of Metastatic Gastric Cancer Patients Treated with Epirubicin, Oxaliplatin and 5-Fluorouracil Combination Chemotherapy. <i>PLoS ONE</i> , 2014, 9, e116027.	1.1	22
61	Reproductive and obstetric outcomes after abdominal radical trachelectomy (ART) for patients with early-stage cervical cancers in Fudan, China. <i>Gynecologic Oncology</i> , 2020, 157, 418-422.	0.6	22
62	Shanghai international consensus on diagnosis and comprehensive treatment of colorectal liver metastases (version 2019). <i>European Journal of Surgical Oncology</i> , 2020, 46, 955-966.	0.5	22
63	Mesothelial cells are not a source of adipocytes in mice. <i>Cell Reports</i> , 2021, 36, 109388.	2.9	22
64	UBTD1 induces cellular senescence through an UBTD1-Mdm2/p53 positive feedback loop. <i>Journal of Pathology</i> , 2015, 235, 656-667.	2.1	21
65	Aflibercept plus FOLFIRI in Asian patients with pretreated metastatic colorectal cancer: a randomized Phase III study. <i>Future Oncology</i> , 2018, 14, 2031-2044.	1.1	20
66	Open vs minimally invasive radical trachelectomy in early-stage cervical cancer: International Radical Trachelectomy Assessment Study. <i>American Journal of Obstetrics and Gynecology</i> , 2022, 226, 97.e1-97.e16.	0.7	20
67	Pertuzumab in combination with trastuzumab and chemotherapy for Chinese patients with HER2-positive metastatic gastric or gastroesophageal junction cancer: a subpopulation analysis of the JACOB trial. <i>Cancer Communications</i> , 2019, 39, 1-10.	3.7	19
68	Genetic variant of PRKAA1 and gastric cancer risk in an eastern Chinese population. <i>Oncotarget</i> , 2015, 6, 42661-42666.	0.8	18
69	Methyl-CpG-binding domain protein 3-like 2 (MBD3L2) promotes Tet2 enzymatic activity for mediating 5mC oxidation. <i>Journal of Cell Science</i> , 2016, 129, 1059-71.	1.2	18
70	Expert opinions on immunotherapy for patients with colorectal cancer. <i>Cancer Communications</i> , 2020, 40, 467-472.	3.7	18
71	Modeling hepatoblastoma development with human fetal liver organoids reveals YAP1 activation is sufficient for tumorigenesis. <i>Protein and Cell</i> , 2022, 13, 683-688.	4.8	18
72	Nimotuzumab combined with gemcitabine versus gemcitabine in K-RAS wild-type locally advanced or metastatic pancreatic cancer: A prospective, randomized-controlled, double-blinded, multicenter, and phase III clinical trial.. <i>Journal of Clinical Oncology</i> , 2022, 40, LBA4011-LBA4011.	0.8	18

#	ARTICLE	IF	CITATIONS
73	DKK4 enhances resistance to chemotherapeutics 5-Fu and YN968D1 in colorectal cancer cells. <i>Oncology Letters</i> , 2017, 13, 587-592.	0.8	17
74	Neutropenia predicts better prognosis in patients with metastatic gastric cancer on a combined epirubicin, oxaliplatin and 5-fluorouracil regimen. <i>Oncotarget</i> , 2015, 6, 39018-39027.	0.8	17
75	Identification of short-form RON as a novel intrinsic resistance mechanism for anti-MET therapy in MET-positive gastric cancer. <i>Oncotarget</i> , 2015, 6, 40519-40534.	0.8	16
76	Associations of potentially functional variants in <i>IL-6</i> , <i>JAKs</i> and <i>STAT3</i> with gastric cancer risk in an eastern Chinese population. <i>Oncotarget</i> , 2016, 7, 28112-28123.	0.8	16
77	Establishment of Cre-mediated HBV recombinant cccDNA (rcccDNA) cell line for cccDNA biology and antiviral screening assays. <i>Antiviral Research</i> , 2018, 152, 45-52.	1.9	16
78	Adaptation of International Guidelines for Metastatic Colorectal Cancer: An Asian Consensus. <i>Clinical Colorectal Cancer</i> , 2014, 13, 145-155.	1.0	15
79	<i>PSCA</i> polymorphisms and gastric cancer susceptibility in an eastern Chinese population. <i>Oncotarget</i> , 2016, 7, 9420-9428.	0.8	15
80	Genetic variant of <i>miR-146a</i> rs2910164 C>G and gastric cancer susceptibility. <i>Oncotarget</i> , 2016, 7, 34316-34321.	0.8	15
81	Expert consensus on maintenance treatment for metastatic colorectal cancer in China. <i>Chinese Journal of Cancer</i> , 2016, 35, 13.	4.9	14
82	An alternatively transcribed <i>TAZ</i> variant negatively regulates <i>JAK</i> & <i>STAT</i> signaling. <i>EMBO Reports</i> , 2019, 20, .	2.0	14
83	Frequency of S492R mutations in the epidermal growth factor receptor: analysis of plasma DNA from patients with metastatic colorectal cancer treated with panitumumab or cetuximab monotherapy. <i>Cancer Biology and Therapy</i> , 2020, 21, 891-898.	1.5	14
84	<i>MUC1</i> gene polymorphism rs4072037 and susceptibility to gastric cancer: a meta-analysis. <i>SpringerPlus</i> , 2014, 3, 599.	1.2	13
85	Efficacy, Safety, and Immunogenicity of HLX04 Versus Reference Bevacizumab in Combination with XELOX or mFOLFOX6 as First-Line Treatment for Metastatic Colorectal Cancer: Results of a Randomized, Double-Blind Phase III Study. <i>BioDrugs</i> , 2021, 35, 445-458.	2.2	13
86	Plasma microRNA-based signatures to predict 3-year postoperative recurrence risk for stage II and III gastric cancer. <i>International Journal of Cancer</i> , 2017, 141, 2093-2102.	2.3	12
87	Preliminary results of a phase 1b study of fruquintinib plus sintilimab in advanced colorectal cancer.. <i>Journal of Clinical Oncology</i> , 2021, 39, 2514-2514.	0.8	12
88	An inhibitor-mediated beta-cell dedifferentiation model reveals distinct roles for FoxO1 in glucagon repression and insulin maturation. <i>Molecular Metabolism</i> , 2021, 54, 101329.	3.0	12
89	Antitumor activity and inhibitory effects on cancer stem cell-like properties of Adeno-associated virus (AAV) -mediated Bmi-1 interference driven by Bmi-1 promoter for gastric cancer. <i>Oncotarget</i> , 2016, 7, 22733-22745.	0.8	12
90	Safety, antitumor activity and biomarkers of sugemalimab in Chinese patients with advanced solid tumors or lymphomas: results from the first-in-human phase I trial. <i>Cancer Immunology, Immunotherapy</i> , 2022, 71, 1897-1908.	2.0	12

#	ARTICLE	IF	CITATIONS
91	Efficacy and safety of HLX10, a novel anti-PD-1 antibody, in patients with previously treated unresectable or metastatic microsatellite instability-high or mismatch repair-deficient solid tumors: A single-arm, multicenter, phase 2 study.. <i>Journal of Clinical Oncology</i> , 2021, 39, 2566-2566.	0.8	11
92	Maintenance treatment of Uracil and Tegafur (UFT) in responders following first-line fluorouracil-based chemotherapy in metastatic gastric cancer: a randomized phase II study. <i>Oncotarget</i> , 2017, 8, 37826-37834.	0.8	11
93	Menstrual pattern after abdominal radical trachelectomy. <i>Oncotarget</i> , 2017, 8, 53146-53153.	0.8	11
94	Prognostic significance and functional implication of immune activating receptor NKG2D in gastric cancer. <i>Biochemical and Biophysical Research Communications</i> , 2017, 487, 619-624.	1.0	10
95	Exploration of modified progression-free survival as a novel surrogate endpoint for overall survival in immuno-oncology trials. , 2021, 9, e002114.		10
96	First-in-human phase I study of anti-HER2 ADC MRG002 in patients with relapsed/refractory solid tumors.. <i>Journal of Clinical Oncology</i> , 2020, 38, TPS1101-TPS1101.	0.8	10
97	Updates in version 2020 of CSCO guidelines for colorectal cancer from version 2019. <i>Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research</i> , 2020, 32, 403-407.	0.7	10
98	Influences of ERCC1, ERCC2, XRCC1, GSTP1, GSTT1, and MTHFR polymorphisms on clinical outcomes in gastric cancer patients treated with EOF chemotherapy. <i>Tumor Biology</i> , 2016, 37, 1753-1762.	0.8	9
99	Amplification and expression of c-MET correlate with poor prognosis of patients with gastric cancer and upregulate the expression of PDL1. <i>Acta Biochimica Et Biophysica Sinica</i> , 2021, 53, 547-557.	0.9	9
100	Prevalence and outcomes of patients (pts) with EGFR S492R ectodomain mutations in ASPECCT: Panitumumab (pmab) vs. cetuximab (cmab) in pts with chemorefractory wild-type KRAS exon 2 metastatic colorectal cancer (mCRC).. <i>Journal of Clinical Oncology</i> , 2015, 33, 740-740.	0.8	9
101	Analysis of plasma protein biomarkers from the phase 3 CONCUR study of regorafenib in Asian patients with metastatic colorectal cancer (mCRC).. <i>Journal of Clinical Oncology</i> , 2016, 34, 672-672.	0.8	9
102	Safety, tolerability, and preliminary pharmacokinetic/pharmacodynamic profile of JMT103 in patients with bone metastases from solid tumors: A multicenter, open-label, dose-escalation, phase I clinical study.. <i>Journal of Clinical Oncology</i> , 2020, 38, 3638-3638.	0.8	9
103	A Phase Ib Study of Lucitanib (AL3810) in a Cohort of Patients with Recurrent and Metastatic Nasopharyngeal Carcinoma. <i>Oncologist</i> , 2022, 27, e453-e462.	1.9	9
104	Genetic polymorphism of the phospholipase C epsilon 1 gene and risk of gastric cancer. <i>Chinese Medical Journal</i> , 2014, 127, 2511-7.	0.9	9
105	STK15 F31I polymorphism is associated with breast cancer risk: a meta-analysis involving 25,014 subjects. <i>Breast Cancer Research and Treatment</i> , 2009, 118, 599-603.	1.1	8
106	Analysis of expression of transcription factors in early human retina. <i>International Journal of Developmental Neuroscience</i> , 2017, 60, 94-102.	0.7	8
107	A multi-center phase II study and biomarker analysis of combined cetuximab and modified FOLFIRI as second-line treatment in patients with metastatic gastric cancer. <i>BMC Cancer</i> , 2017, 17, 188.	1.1	8
108	Regorafenib in Chinese patients with metastatic colorectal cancer: Subgroup analysis of the phase 3 <sc>CONCUR</sc> trial. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2020, 35, 1307-1316.	1.4	8

#	ARTICLE	IF	CITATIONS
109	Safety Profile and Adverse Events of Special Interest for Fruquintinib in Chinese Patients with Previously Treated Metastatic Colorectal Cancer: Analysis of the Phase 3 FRESKO Trial. <i>Advances in Therapy</i> , 2020, 37, 4585-4598.	1.3	8
110	A randomized, double-blind, parallel-group, placebo-controlled, multicenter, phase II clinical study of famitinib in the treatment of advanced metastatic colorectal cancer. <i>Journal of Clinical Oncology</i> , 2015, 33, 513-513.	0.8	8
111	Associations of genotypes and haplotypes of IL-17 with risk of gastric cancer in an eastern Chinese population. <i>Oncotarget</i> , 2016, 7, 82384-82395.	0.8	8
112	Genomic Profiling of Chinese Cervical Cancer Patients Reveals Prevalence of DNA Damage Repair Gene Alterations and Related Hypoxia Feature. <i>Frontiers in Oncology</i> , 2021, 11, 792003.	1.3	8
113	A new method of surgical margin assuring for abdominal radical trachelectomy in frozen section. <i>European Journal of Cancer</i> , 2015, 51, 734-741.	1.3	7
114	An integrated analysis of cancer genes in clear cell renal cell carcinoma. <i>Future Oncology</i> , 2017, 13, 715-725.	1.1	7
115	Phase II study of 5-FU plus leucovorin in patients with metastatic colorectal cancer: Regimen of 1 week on, 1 week off. <i>Cancer Science</i> , 2017, 108, 2045-2051.	1.7	7
116	DNA-nanorobot-guided thrombin-inducing tumor infarction: raising new potential clinical concerns. <i>Drug Discovery Today</i> , 2020, 25, 951-955.	3.2	7
117	A Phase I/II trial of fruquintinib in combination with paclitaxel for second-line treatment in patients with advanced gastric cancer. <i>Journal of Clinical Oncology</i> , 2017, 35, 128-128.	0.8	7
118	Abdominal scar characteristics as a predictor of cervical stenosis after abdominal radical trachelectomy. <i>Oncotarget</i> , 2016, 7, 37755-37761.	0.8	7
119	Updates in version 2019 of CSCO guidelines for colorectal cancer from version 2018. <i>Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research</i> , 2019, 31, 423-425.	0.7	7
120	Outcomes by hypomagnesemia (hypomag) in the randomized phase III ASPECCT trial of patients (pts) with chemorefractory wild-type (WT) KRAS exon 2 metastatic colorectal cancer (mCRC). <i>Journal of Clinical Oncology</i> , 2016, 34, 507-507.	0.8	7
121	Genetic variant rs4072037 of MUC1 and gastric cancer risk in an Eastern Chinese population. <i>Oncotarget</i> , 2016, 7, 15930-15936.	0.8	6
122	Anticancer drug R&D landscape in China. <i>Journal of Hematology and Oncology</i> , 2020, 13, 51.	6.9	6
123	Phase II study of weekly irinotecan and capecitabine treatment in metastatic colorectal cancer patients. <i>BMC Cancer</i> , 2014, 14, 986.	1.1	5
124	A multicenter clinical study: personalized medication for advanced gastrointestinal carcinomas with the guidance of patient-derived tumor xenograft (PDTX). <i>Journal of Cancer Research and Clinical Oncology</i> , 2022, 148, 673-684.	1.2	5
125	Subgroup analysis by prior anti-VEGF for anti-EGFR target therapy in FRESKO, a randomized, double-blind, Phase III trial. <i>Future Oncology</i> , 2021, 17, 1339-1350.	1.1	5
126	Efficacy and tolerability of bevacizumab (BEV) plus capecitabine and cisplatin (XP) in Chinese patients (pts) with locally advanced or metastatic gastric/gastroesophageal junction cancer (AGC): Results from the AVATAR study. <i>Journal of Clinical Oncology</i> , 2012, 30, 73-73.	0.8	5

#	ARTICLE	IF	CITATIONS
127	S-1 monotherapy as second line chemotherapy in advanced gastric cancer patients previously treated with cisplatin/infusional fluorouracil. <i>International Journal of Clinical and Experimental Pathology</i> , 2014, 7, 4274-9.	0.5	5
128	Safety and efficacy of aprepitant as mono and combination therapy for the prevention of emetogenic chemotherapy-induced nausea and vomiting: post-marketing surveillance in China. <i>Chinese Clinical Oncology</i> , 2020, 9, 68-68.	0.4	4
129	UHRF1 regulates alternative splicing by interacting with splicing factors and U snRNAs in a H3R2me involved manner. <i>Human Molecular Genetics</i> , 2021, 30, 2110-2122.	1.4	4
130	A phase 1b study of VEGFR inhibitor fruquintinib in patients with pretreated advanced colorectal cancer.. <i>Journal of Clinical Oncology</i> , 2014, 32, 3548-3548.	0.8	4
131	A randomized, double-blind, placebo-controlled, multi-centered phase 3 trial comparing fruquintinib versus placebo plus best supportive care in Chinese patients with metastatic colorectal cancer (FRESCO).. <i>Journal of Clinical Oncology</i> , 2017, 35, 3508-3508.	0.8	4
132	Efficacy of panitumumab (pmab) vs. cetuximab (cmab) in patients (pts) with wild-type (WT) KRAS exon 2 metastatic colorectal cancer (mCRC) treated with prior bevacizumab (bev): Results from ASPECCT.. <i>Journal of Clinical Oncology</i> , 2016, 34, 519-519.	0.8	4
133	Progressive resistance exercise training to prevent lower-limb lymphedema after cervical cancer surgery: A feasibility study. <i>Asia-Pacific Journal of Oncology Nursing</i> , 2022, 9, 32-38.	0.7	4
134	mPEG-PDLLA Micelles Potentiate Docetaxel for Intraperitoneal Chemotherapy in Ovarian Cancer Peritoneal Metastasis. <i>Frontiers in Pharmacology</i> , 2022, 13, 861938.	1.6	4
135	Effects of variant rs346473 in ARHGAP24 gene on disease progression of HBV infection in han Chinese population. <i>Journal of Huazhong University of Science and Technology [Medical Sciences]</i> , 2011, 31, 482-487.	1.0	3
136	Phase I Dose-Escalation Study of Ramucirumab in Chinese Patients with Advanced Solid Tumors. <i>Oncologist</i> , 2017, 22, 638-e56.	1.9	3
137	Improving pregnancy outcomes in fertility preserved cervical cancer patients: big challenge after radical trachelectomy. <i>Journal of Gynecologic Oncology</i> , 2019, 30, e73.	1.0	3
138	A post-hoc health-related quality of life (HRQoL) analysis of patients with metastatic colorectal cancer (mCRC) in the phase III CONCUR trial.. <i>Journal of Clinical Oncology</i> , 2015, 33, 667-667.	0.8	3
139	Impact of primary tumor location (TL) on outcomes of first-line (1L) FOLFOX-4 (F) ± cetuximab (cet) in patients (pts) with RAS wild-type (wt) metastatic colorectal cancer (mCRC) in the phase 3 TAILOR trial.. <i>Journal of Clinical Oncology</i> , 2017, 35, 683-683.	0.8	3
140	Final overall survival (OS) analysis of first-line (1L) FOLFOX-4 ± cetuximab (cet) in patients (pts) with RAS wild-type (wt) metastatic colorectal cancer (mCRC) in the phase 3 TAILOR trial.. <i>Journal of Clinical Oncology</i> , 2018, 36, 3521-3521.	0.8	3
141	Initial dose of apatinib in Chinese patients with chemotherapy-refractory advanced or metastatic adenocarcinoma of stomach or gastroesophageal junction in third- or later-line setting: 500 mg or 850 mg?. <i>Journal of Clinical Oncology</i> , 2018, 36, 35-35.	0.8	3
142	Treatment patterns and outcomes in Chinese gastric cancer by HER2 status: A non-interventional registry study (EVIDENCE).. <i>Journal of Clinical Oncology</i> , 2019, 37, 4025-4025.	0.8	3
143	Effects of regorafenib (REG) therapy on health-related quality of life (HRQoL) in patients with metastatic colorectal cancer (mCRC) in the phase III CONCUR trial.. <i>Journal of Clinical Oncology</i> , 2015, 33, 3560-3560.	0.8	3
144	Time to raise the bar: Transition rate of phase 1 programs on anticancer drugs. <i>Cancer Cell</i> , 2022, 40, 233-235.	7.7	3

#	ARTICLE	IF	CITATIONS
145	Phase I dose-escalating study of S-1 in combination with oxaliplatin for patients with advanced and/or metastatic colorectal cancer. <i>Anti-Cancer Drugs</i> , 2008, 19, 745-748.	0.7	2
146	Reply to C. Kersten et al and D.A. Parikh et al. <i>Journal of Clinical Oncology</i> , 2019, 37, 1592-1593.	0.8	2
147	A phase I study of a TGF- β 2 receptor I kinase inhibitor YL-13027 in patients with advanced solid tumors.. <i>Journal of Clinical Oncology</i> , 2021, 39, 3098-3098.	0.8	2
148	Quality-adjusted survival in patients with metastatic colorectal cancer treated with fruquintinib in the FRESKO trial. <i>Future Oncology</i> , 2021, 17, 1923-1931.	1.1	2
149	Comparison of efficacy and safety of second-line palliative chemotherapy with paclitaxel plus raltitrexed and paclitaxel alone in patients with metastatic gastric adenocarcinoma: A randomized phase II trial.. <i>Journal of Clinical Oncology</i> , 2019, 37, 4054-4054.	0.8	2
150	Association between hand-foot skin reaction (HFSR) and survival benefit of fruquintinib in FRESKO trial.. <i>Journal of Clinical Oncology</i> , 2019, 37, e15012-e15012.	0.8	2
151	LRP5 polymorphism-A potential predictor of the clinical outcome in advanced gastric cancer patients treated with EOF regimen. <i>Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research</i> , 2014, 26, 478-85.	0.7	2
152	Phase II study of mitomycin C and cisplatin in heavily pretreated advanced breast cancer. <i>Chinese-German Journal of Clinical Oncology</i> , 2006, 5, 442-445.	0.1	1
153	Immunohistochemical study of nuclear factor- κ B activity in colorectal cancer. <i>Chinese-German Journal of Clinical Oncology</i> , 2011, 10, 406-409.	0.1	1
154	Single- and multiple-dose pharmacokinetics, safety and tolerability of zibotentan (ZD4054) in Chinese men with advanced solid tumors. <i>Cancer Chemotherapy and Pharmacology</i> , 2012, 70, 57-63.	1.1	1
155	Influence of hypoxia-related genetic polymorphisms on the prognosis of patients with metastatic gastric cancer treated with EOF. <i>Oncology Letters</i> , 2017, 15, 1334-1342.	0.8	1
156	Reply to P. Di Nardo et al and R. Sun et al. <i>Journal of Clinical Oncology</i> , 2018, 36, 1380-1381.	0.8	1
157	CS1001-304: A phase III study of fluorouracil and cisplatin (FP) with CS1001, an anti-PD-L1 antibody, or placebo in unresectable locally advanced, recurrent or metastatic esophageal squamous cell carcinoma (ESCC).. <i>Journal of Clinical Oncology</i> , 2021, 39, TPS255-TPS255.	0.8	1
158	Subgroup Analysis by Liver Metastasis in the FRESKO Trial Comparing Fruquintinib versus Placebo Plus Best Supportive Care in Chinese Patients with Metastatic Colorectal Cancer. <i>OncoTargets and Therapy</i> , 2021, Volume 14, 4439-4450.	1.0	1
159	Effects of regorafenib therapy on health-related quality of life (HRQoL) in patients with metastatic colorectal cancer (mCRC) in the phase III CONCUR trial.. <i>Journal of Clinical Oncology</i> , 2015, 33, 697-697.	0.8	1
160	Subgroup analysis by prior anti-VEGF or anti-EGFR target therapy in FRESKO, a randomized, double-blind, phase 3 trial comparing fruquintinib versus placebo plus best supportive care in Chinese patients with metastatic colorectal cancer (mCRC).. <i>Journal of Clinical Oncology</i> , 2018, 36, 3537-3537.	0.8	1
161	Quality-adjusted time without symptoms or toxicity (Q-TWiST) of patients with metastatic colorectal cancer (mCRC) treated with fruquintinib in the randomized phase III FRESKO trial.. <i>Journal of Clinical Oncology</i> , 2018, 36, 3544-3544.	0.8	1
162	Development of non-hematological adverse events in apatinib-treated gastric cancer and their association with clinical outcome: Results from a phase IV study.. <i>Journal of Clinical Oncology</i> , 2018, 36, 4039-4039.	0.8	1

#	ARTICLE	IF	CITATIONS
163	Safety of apatinib as third-line or beyond treatment in advanced or metastatic gastric cancer: Results from a multicenter phase IV study (Ahead-G201).. Journal of Clinical Oncology, 2018, 36, e16019-e16019.	0.8	1
164	A phase Ia/Ib trial of the anti-PD-L1 human monoclonal antibody (mAb), CS1001, in patients (pts) with advanced solid tumors or lymphomas.. Journal of Clinical Oncology, 2019, 37, 2526-2526.	0.8	1
165	Early carcinoembryonic antigen (CEA) dynamics to predict fruquintinib efficacy in FRESKO, a 3+ line metastatic colorectal carcinoma (mCRC) phase III trial.. Journal of Clinical Oncology, 2020, 38, e16001-e16001.	0.8	1
166	First-in-human (FIH) phase I study of GST-HG161, a potent and highly selective c-met inhibitor, in patients with advanced solid tumor.. Journal of Clinical Oncology, 2020, 38, e16126-e16126.	0.8	1
167	S-1 monotherapy as second line chemotherapy in advanced gastric cancer patients previously treated with cisplatin/infusional fluorouracil. International Journal of Clinical and Experimental Pathology, 2014, 7, 3293-8.	0.5	1
168	Safety, tolerability, and preliminary antitumor activity of sitravatinib plus tislelizumab (TIS) in patients (pts) with unresectable locally advanced or metastatic gastric cancer/gastroesophageal junction cancer (GC/GEJC).. Journal of Clinical Oncology, 2022, 40, 281-281.	0.8	1
169	Reply to S. Zhang, L. Fornaro et al, and H.J. Lee et al. Journal of Clinical Oncology, 2016, 34, 3823-3824.	0.8	0
170	Clinical effectiveness of apatinib at different doses in patients with advanced gastric cancer as the third-line or further treatment: Results from a post-marketing phase IV study.. Journal of Clinical Oncology, 2021, 39, e16037-e16037.	0.8	0
171	A phase Ib study of the PI3KÎ inhibitor liperlisib in patients with advanced solid tumors.. Journal of Clinical Oncology, 2021, 39, 3099-3099.	0.8	0
172	Safety and efficacy of apatinib as third or later line treatment for advanced gastric cancer or gastroesophageal junction adenocarcinoma: A post-marketing phase IV study.. Journal of Clinical Oncology, 2021, 39, e16034-e16034.	0.8	0
173	WX390, a high-potent PI3K-mTOR dual inhibitor, first-in-human (FIH) phase I study in advanced relapsed or refractory solid tumor, and lymphoma.. Journal of Clinical Oncology, 2021, 39, 3106-3106.	0.8	0
174	Ultrasoundâ€guided percutaneous transluminal angioplasty for the treatment of cephalic arch stenosis in hemodialysis arteriovenous fistulas. Seminars in Dialysis, 2021, , .	0.7	0
175	Effects of IGF2BP2, KCNQ1, and GCKR polymorphisms on clinical outcome in metastatic gastric cancer treated with EOF regimen.. Journal of Clinical Oncology, 2015, 33, 64-64.	0.8	0
176	Post-hoc analyses of overall survival (OS) and progression-free survival (PFS) in the TRIO-013/LOGiC trial of lapatinib (L) in combination with capecitabine plus oxaliplatin (CapeOx).. Journal of Clinical Oncology, 2015, 33, 133-133.	0.8	0
177	Randomized phase III study of panitumumab (pmab) vs. cetuximab (cmab) in chemorefractory wild-type (WT) KRAS exon 2 metastatic colorectal cancer (mCRC): Outcomes by hypomagnesemia (hypomag) in ASPECCT.. Journal of Clinical Oncology, 2015, 33, 705-705.	0.8	0
178	Efficacy of panitumumab vs cetuximab in patients with wild-type KRAS exon 2 metastatic colorectal cancer treated with prior bevacizumab: Results from ASPECCT.. Journal of Clinical Oncology, 2016, 34, 3538-3538.	0.8	0
179	Outcomes by hypomagnesemia in the randomized phase III ASPECCT trial in patients with chemorefractory wild-type KRAS exon 2 metastatic colorectal cancer (mCRC).. Journal of Clinical Oncology, 2016, 34, e15050-e15050.	0.8	0
180	A phase III trial (ZJBIO009): CMAB009 plus irinotecan versus irinotecan alone as second-line treatment after fluoropyrimidine and oxaliplatin failure in wild-type K-ras metastatic colorectal cancer patients.. Journal of Clinical Oncology, 2017, 35, 3513-3513.	0.8	0

#	ARTICLE	IF	CITATIONS
181	Comparison of efficacy and safety of first-line palliative chemotherapy with TX and XELOX regimens in patients with metastatic gastric adenocarcinoma: A randomized phase II trial.. Journal of Clinical Oncology, 2017, 35, 4070-4070.	0.8	0
182	Early presence of antiangiogenesis-related adverse events as a potential biomarker of antitumor efficacy in patients with metastatic gastric cancer treated with apatinib.. Journal of Clinical Oncology, 2017, 35, 4052-4052.	0.8	0
183	Effect of region and hospital attribute on outcome of gastric patients treated with apatinib: Data from post-marketing phase IV study.. Journal of Clinical Oncology, 2018, 36, 40-40.	0.8	0
184	Apatinib as third-line or beyond therapy in patients with chemotherapy-refractory advanced or metastatic adenocarcinoma of stomach or gastroesophageal junction: An open-label, multicenter, post-marketing phase IV study (Ahead-G201).. Journal of Clinical Oncology, 2018, 36, 103-103.	0.8	0
185	Association of proteinuria, hypertension, and hand-foot-skin reaction with efficacy of apatinib in gastric cancer: Results from the post-marketing study (Ahead-G201).. Journal of Clinical Oncology, 2018, 36, 73-73.	0.8	0
186	Safety and efficacy of apatinib in elderly patients with advanced or metastatic gastric cancer in the post-marketing phase IV study: Subgroup analysis by age (Ahead-G201).. Journal of Clinical Oncology, 2018, 36, 126-126.	0.8	0
187	Prognostic factors for survival in apatinib-treated gastric cancer: Results from a post-marketing phase IV study (Ahead-G201).. Journal of Clinical Oncology, 2018, 36, 19-19.	0.8	0
188	Comparisons between intestinal and diffuse gastric cancer in response to apatinib: Data from post-marketing phase IV study.. Journal of Clinical Oncology, 2018, 36, 36-36.	0.8	0
189	Effects of apatinib dose interruptions on safety and efficacy in patients with chemotherapy-refractory advanced or metastatic adenocarcinoma of stomach or gastroesophageal junction in third- or later-line setting.. Journal of Clinical Oncology, 2018, 36, 142-142.	0.8	0
190	Does hypertension history in patients with advanced gastric cancer has an impact on clinical outcomes following apatinib treatment? A subgroup analysis based on data from Ahead-G201 study.. Journal of Clinical Oncology, 2018, 36, e16022-e16022.	0.8	0
191	BMI differences for clinical outcome in patients with advanced or metastatic gastric cancer treated with apatinib: Data from a post-marketing phase IV study (Ahead-G201).. Journal of Clinical Oncology, 2018, 36, e16027-e16027.	0.8	0
192	Impact of time to progression on first-line therapy on clinical outcomes in advanced gastric cancer treated with apatinib: data from a phase IV study (Ahead-G201).. Journal of Clinical Oncology, 2018, 36, e16021-e16021.	0.8	0
193	Clinical benefit of continuing apatinib beyond progression in advanced or metastatic gastric cancer.. Journal of Clinical Oncology, 2018, 36, e16020-e16020.	0.8	0
194	Effect of ECOG PS on outcome of advanced or metastatic gastric patients treated with apatinib: Analysis from a post-marketing phase IV study.. Journal of Clinical Oncology, 2018, 36, e16026-e16026.	0.8	0
195	Response to apatinib by the number of metastatic organs in patients with advanced or metastatic gastric cancer: Subgroup analysis from a phase IV study (Ahead-G201).. Journal of Clinical Oncology, 2018, 36, e16028-e16028.	0.8	0
196	Sequencing of different targeted therapies in management of KRAS wild-type metastatic colorectal cancer: A meta-analysis.. Journal of Clinical Oncology, 2019, 37, 679-679.	0.8	0
197	Camrelizumab plus famitinib in patients with metastatic colorectal cancer: Results from an open-label, multicenter phase II basket study.. Journal of Clinical Oncology, 2022, 40, 3577-3577.	0.8	0
198	Preliminary results of raltitrexed in Chinese patients with metastatic colorectal cancer: A prospective, multicenter, real-world study.. Journal of Clinical Oncology, 2022, 40, 3591-3591.	0.8	0

#	ARTICLE	IF	CITATIONS
199	Updated efficacy and safety results from the phase 2 study of serplulimab, a novel anti-PD-1 antibody, in patients with previously treated unresectable or metastatic microsatellite instability-high or mismatch repair-deficient solid tumors.. Journal of Clinical Oncology, 2022, 40, 2592-2592.	0.8	0